Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss

Mutations in mitochondrial DNA have been reported as associated with non-syndromic and aminoglycoside-induced hearing loss. In the present study, we have performed mutational screening of entire 12S rRNA gene in 250 unrelated patients with non-syndromic and aminoglycoside-induced hearing loss. Twenty-one different homoplasmic sequence variants were identified, including eight common polymorphisms, one deafness-associated mutation m.1555 A>G and three putatively pathogenic variants: m.669 T>C, m.827 A>G, m.961 delT+C(n)ins. The incidence of m.1555 A>G was estimated for 3.6% (9/250); however, where aminoglycoside exposure was taken as a risk factor, the frequency was 5.5% (7/128). Substitution m.669 T>C was identified only in patients with hearing impairment and episode of aminoglycoside exposure, which may suggest that such additional risk factors must appear to induce clinical phenotype. Moreover, two 12S rRNA sequence variants: m.988 G>A and m.1453 A>G, localized at conserved sites and affected RNA secondary structure, may be new candidates for non-syndromic and aminoglycoside-induced hearing loss associated mutations.     

Multiple ASF/SF2 Sites in the Human Papillomavirus Type 16 (HPV-16) E4-Coding Region Promote Splicing to the Most Commonly Used 3′-Splice Site on the HPV-16 Genome

Our results presented here demonstrate that the most abundant human papillomavirus type 16 (HPV-16) mRNAs expressing the viral oncogenes E6 and E7 are regulated by cellular ASF/SF2, itself defined as a proto-oncogene and overexpressed in cervical cancer cells. We show that the most frequently used 3′-splice site on the HPV-16 genome, site SA3358, which is used to produce primarily E4, E6, and E7 mRNAs, is regulated by ASF/SF2. Splice site SA3358 is immediately followed by 15 potential binding sites for the splicing factor ASF/SF2. Recombinant ASF/SF2 binds to the cluster of ASF/SF2 sites. Mutational inactivation of all 15 sites abolished splicing to SA3358 and redirected splicing to the downstream-located, late 3′-splice site SA5639. Overexpression of a mutant ASF/SF2 protein that lacks the RS domain, also totally inhibited the usage of SA3358 and redirected splicing to the late 3′-splice site SA5639. The 15 ASF/SF2 binding sites could be replaced by an ASF/SF2-dependent, HIV-1-derived splicing enhancer named GAR. This enhancer was also inhibited by the mutant ASF/SF2 protein that lacks the RS domain. Finally, silencer RNA (siRNA)-mediated knockdown of ASF/SF2 caused a reduction in spliced HPV-16 mRNA levels. Taken together, our results demonstrate that the major HPV-16 3′-splice site SA3358 is dependent on ASF/SF2. SA3358 is used by the most abundantly expressed HPV-16 mRNAs, including those encoding E6 and E7. High levels of ASF/SF2 may therefore be a requirement for progression to cervical cancer. This is supported by our earlier findings that ASF/SF2 is overexpressed in high-grade cervical lesions and cervical cancer.Human papillomavirus type 16 (HPV-16) is the foremost cause of cervical cancer, which is one of the most common cancers in women globally (10, 37). Persistence of high-risk HPV types, such as HPV-16, is the highest risk factor for the development of cervical cancer. The majority of all DNA viruses that establish persistence have evolved a highly organized gene expression program, often divided into clear early and late phases. The HPV-16 genome contains an early promoter that could potentially express mRNAs encoding all viral gene products, and a late differentiation-dependent promoter that specifically excludes expression of E6 and E7 (21). The switch from early to late gene expression includes a promoter switch as well as derepression and activation of the late poly(A) signal and late splice sites (16). To activate late splice sites and the late poly(A) signal, many early splice sites and the early poly(A) signal must be downregulated to allow for competition from mutually exclusive late splice sites and poly(A) signal (8, 26, 36). Other HPV-16 splice sites are used by both early and late mRNAs and should function well in both mitotic cells and terminally differentiated cells. One of the major splice sites used by both early and late mRNAs is SA3358 (Fig. ​(Fig.1A).1A). This splice site is outstanding in that it is used to produce the majority of all HPV-16 mRNAs, including the mRNAs of the oncogenes E6 and E7 and the E4, E5, L1, and perhaps L2 proteins. In contrast, efficient usage of SA3358 specifically prevents expression of HPV-16 E1 and E2.Open in a separate windowFIG. 1.(A) Schematic representation of the HPV-16 genome. Early and late viral promoters p97 and p670 are indicated. Numbers indicate nucleotide positions of 5′-splice sites (filled circles), 3′-splice sites (open circles), or early and late poly(A) signals pAE and pAL, respectively. LCR, long control region. A few selected early and late mRNAs are shown (1). Previously described splicing silencers and enhancers are indicated (24, 34, 35). (B) Diagram with potential ASF/SF2 sites upstream and downstream of SD3632 predicted by ESEfinder (4). Heights of the bars represent degrees of similarity to ASF/SF2 binding sites according to ESEfinder. HPV-16 splice sites SA3358 and SD3632 are indicated. Numbers indicate nucleotide positions in the HPV-16 genome. The position of a previously described enhancer is indicated (24). (C) ASF/SF2 sites in the mutant HPV-16 sequence in which the ASF/SF2 sites had been inactivated, as predicted by ESEfinder (4). (D) Exact sequences of the wt and mutant (mut) HPV-16 Predicted sequences between nucleotide positions 3407 and 3627 in the HPV-16 genome. Dots represent identical nucleotides.Many, if not all, HPV types contain a 3′-splice site in the E4 open reading frame (orf) that is spliced to an upstream 5′-splice site that joins the E1 AUG with the E4 orf. In HPV-16, these splice sites are named SA3358 and SD880 (Fig. ​(Fig.1A),1A), whereas they are named SD847 and SA3325 in HPV-11 and SD877 and SA3295 in HPV-31 (1). Splicing between HPV-16 SD880 and SA3358 (6, 9, 27), or the corresponding sites in HPV-11 (5, 20, 23) and HPV-31 (11, 12), occurs on the most-common early mRNAs encoding E6 and E7, as well as on the most-abundant late mRNA encoding E4. In addition, the most-common L1 mRNA is also spliced between SD880 and SA3358 (17), or the corresponding sites in HPV-11 (23) and HPV-31 (12, 22). Analysis of HPV-16 splicing in cervical scrape samples revealed that splicing between SD880 and SA3358 was the most-common splicing event in both low- and high-grade cervical lesions (25). In vitro transfection experiments demonstrated that splicing to SA3358 was required for efficient expression of E6 and E7 (2). As a matter of fact, splicing between SD880 and SA3358 was required for production of E6 and E7 quantities that were needed for transformation of cells by these HPV proteins. In HPV-31, SA3295 corresponds to HPV-16 SA3358. Mutational inactivation of HPV-31 SA3295 in an infectious molecular clone of HPV-31 immediately caused splicing to a cryptic 3′-splice site located three nucleotides further down (15). These results indicated that HPV-31 SA3295 is under the control of strong splicing enhancer elements and that there is a strong pressure on the virus to maintain a 3′-splice site in that exact region.We have previously reported that HPV-16 SA3358 has an exceptionally poor 3′-splice site sequence compared to a consensus 3′-splice site (24). This is due primarily to an almost complete absence of an upstream row of uninterrupted pyrimidines that normally characterize an efficiently utilized 3′-splice site. However, SA3358 is one of the most efficiently used splice sites on the HPV-16 genome (24, 33). We have previously shown that utilization of HPV-16 SA3358 is totally dependent on exonic sequences downstream of SA3358, and we concluded that a splicing enhancer was located downstream of SA3358 (24). Here, we have followed up these findings; we demonstrate that the enhancer elements downstream of HPV-16 SA3358 are binding sites for ASF/SF2, and we show that ASF/SF2 enhances splicing to SA3358.     

DARPin-Assisted Crystallography of the CC2-LZ Domain of NEMO Reveals a Coupling between Dimerization and Ubiquitin Binding

NEMO is an integral part of the IκB kinase complex and serves as a molecular switch by which the NF-κB signaling pathway can be regulated. Oligomerization and polyubiquitin (poly-Ub) binding, mediated through the regulatory CC2-LZ domain, were shown to be key features governing NEMO function, but the relationship between these two activities remains unclear. In this study, we solved the structure of this domain in complex with a designed ankyrin repeat protein, which helps its crystallization. We generated several NEMO mutants in this domain, including those associated with human diseases incontinentia pigmenti and immunodeficiency with or without anhidrotic ectodermal dysplasia. Analytical ultracentrifugation and thermal denaturation experiments were used to evaluate the dimerization properties of these mutants. A fluorescence-based assay was developed, as well, to quantify the interaction to monoubiquitin and poly-Ub chains. Moreover, the effect of these mutations was investigated for the full-length protein. We show that a proper folding of the ubiquitin-binding domain, termed NOA/UBAN/NUB, into a stable coiled-coil dimer is required but not sufficient for efficient interaction with poly-Ub. In addition, we show that binding to poly-Ub and, to a lesser extent, to monoubiquitin increases the stability of the NOA coiled-coil dimer. Collectively, these data provide structural insights into how several pathological mutations within and outside of the CC2-LZ's NOA ubiquitin binding site affect IκB kinase activation in the NF-κB signaling pathway.     

The TRAF2 and TRAF6 expression in myomas and myometrium of women in reproduction and perimenopausal age

Uterine myomas represent one of the most common female diseases. Uterine myomas or fibromas are benign, hormone-responding tumours of, respectively, smooth muscles and fibroblasts and their aetiology induces a significant interest. In myomas the presence of aromatase was detected and, in addition, oestrogen was found to be synthesized in myoma cells. The studies were performed on myoma patients of generative age and those in peri-menopausal age. Expression of TRAF2 and TRAF6 proteins was examined using immunohistochemistry and Western blot approach in small and large uterine myomas isolated from women of various age. In addition, the evaluation was conducted at the periphery of every myoma. We indicated that the level of both tested proteins in myomas is higher than in control. TRAF2 level in myometrium was lower than in myomas but higher than in control. In the case of TRAF6 those changes were ambiguous. Age didn't have influence the level of expression in both tested TRAF in studied structures.     

The connective tissue response to Ti, NiCr and AgPd alloys

The aim of the study was to compare the connective tissue response of Lewis rats to Ti, NiCr and AgPd alloys. It was found that implants were covered by collagen-rich, well vascularized capsules. Titanium was covered by the thinnest capsule (57 ± 20 μm) and AgPd alloy was covered by the thickest capsule (239 ± 50 μm). The PCNA+ cell prevalence in the capsules was lower for titanium than for AgPd and NiCr. Mast cells formed a gradient to a depth of 1200 μm only for titanium implants. Cells with brown to black silver granules in the cytoplasm were observed close to AgPd implants. The results suggest that titanium implants induce a weaker connective tissue response than implants made from NiCr and AgPd alloys.     

Design,synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity

Six compounds were synthesized with piperazine in linker region and hydroxamate as Zinc Binding Group (ZBG). They were screened against three cancer cell-lines (NCIH460; HCT116; U251). Compounds 5c and 5f with GI₅₀ value of 9.33 ± 1.3 μM and 12.03 ± 4 μM, respectively, were tested for their inhibitory potential on hHDAC8. Compound 5c had IC₅₀ of 33.67 μM. Compounds were also screened for their anticancer activity against HL60 human promyelocytic leukemia cell line due to the presence of pharmacophoric features of RR inhibitors in them. Compound 5c had IC₅₀ of 0.6 μM at 48 h.     

High-pressure freezing combined with in vivo-DAB-cytochemistry: A novel approach for studies of endocytic compartments

Methods for fine structural and functional analyses of complex and dynamic cell compartments must ensure high temporal resolution together with an excellent fine structural preservation. High-pressure freezing followed by freeze-substitution, and resin embedding is state of the art but its use is limited in combination with preembedding cytochemical techniques. Here we show a new approach for the exploration of compartments of the endocytosis system, which combines high-pressure freezing with peroxidase-catalyzed cytochemistry, thus using the potencies of both synergistically. Uptake of horseradish peroxidase-labeled molecules is followed by in vivo-staining and immobilization of endocytic compartments by generation of diaminobenzidine precipitates. Subsequently, the specimens are high pressure frozen, freeze-substituted, and embedded in resin. The excellent fine structural preservation, together with the high temporal resolution, and differentiating visualization of endocytic compartments qualify the new approach for morpho-functional studies of the complex and dynamic components of the endocytosis system involved in physiologic and pathologic cellular traffic, and in routes utilized in drug targeting strategies. The distinct appearances of membranes and reactive compartments provide optimal conditions for 3D-analyses by electron tomography allowing to discern subtle details of the complex 3D-structures of endocytic compartments.     

Characterization of purified human Bact spliceosomal complexes reveals compositional and morphological changes during spliceosome activation and first step catalysis

To better understand the compositional and structural dynamics of the human spliceosome during its activation, we set out to isolate spliceosomal complexes formed after precatalytic B but prior to catalytically active C complexes. By shortening the polypyrimidine tract of the PM5 pre-mRNA, which lacks a 3' splice site and 3' exon, we stalled spliceosome assembly at the activation stage. We subsequently affinity purified human B(act) complexes under the same conditions previously used to isolate B and C complexes, and analyzed their protein composition by mass spectrometry. A comparison of the protein composition of these complexes allowed a fine dissection of compositional changes during the B to B(act) and B(act) to C transitions, and comparisons with the Saccharomyces cerevisiae B(act) complex revealed that the compositional dynamics of the spliceosome during activation are largely conserved between lower and higher eukaryotes. Human SF3b155 and CDC5L were shown to be phosphorylated specifically during the B to B(act) and B(act) to C transition, respectively, suggesting these modifications function at these stages of splicing. The two-dimensional structure of the human B(act) complex was determined by electron microscopy, and a comparison with the B complex revealed that the morphology of the human spliceosome changes significantly during its activation. The overall architecture of the human and S. cerevisiae B(act) complex is similar, suggesting that many of the higher order interactions among spliceosomal components, as well as their dynamics, are also largely conserved.     

Functional analysis of an intergenic non-coding sequence within <Emphasis Type="Italic">mce1</Emphasis> operon of <Emphasis Type="Italic">M.tuberculosis</Emphasis>

Background  

The mce operons play an important role in the entry of M. tuberculosis into macrophages and non-phagocytic cells. Their non-redundant function as well as complex regulation is implied by the phenotype of mce mutants. Recently, mce1 operon was found to extend over 13 genes, fadD5 (Rv0166) being the first gene of the operon. The presence of a non-coding sequence of 200 base pairs between Rv0166 and Rv0167 is peculiar to mce1 among the four mce operons of M.tuberculosis. We have examined the function of this region.